Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | JAK1 | P23458 | 3/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5729349 | 0.97 | S1PR1 (0.33) | S1PR1ESR1ESR2SLC6A2SLC6A3 | |
| SCHEMBL6307449 | 0.88 | PTGS1 (0.35) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL5729705 | 0.87 | ESR1 (0.35) | S1PR1ESR1ESR2 | |
| SCHEMBL5729286 | 0.85 | PTGS1 (0.34) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL6304492 | 0.83 | MLLT1 (0.34) | — | |
| SCHEMBL5731066 | 0.82 | PTGS1 (0.34) | ESR1ESR2 | |
| SCHEMBL5729633 | 0.82 | SLC6A2 (0.37) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL5729513 | 0.82 | SLC6A2 (0.37) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL5729411 | 0.81 | ESR1 (0.36) | ESR1ESR2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL5729312 | 0.81 | PTGS1 (0.34) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869969-B2 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | CHIRON CORPORATION | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | ESR2, GPER1, ESR1 | S1PR1 376/4885ESR1 3/4885ESR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.